Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023

Press Release Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today presented key topline data from the pivotal Phase 3 BRIO-I clinical trial….

Related Keywords

United Kingdom ,Seattle ,Washington ,United States ,Paul Sagan ,Michele Gray ,Ben Bergo ,Almamoun Abdelkader ,Herb Kaufman ,April Dovorany ,Visus Therapeutics Inc ,Us Census Bureau ,Population Division ,Eye Care Trade ,Linkedin ,Twitter ,Drug Administration ,Instagram ,Business Biotech ,Reported Outcome Measures ,Therapeutics Inc ,Binocular Near Visual Acuity ,Visus Therapeutics ,Early Treatment ,Diabetic Retinopathy ,Retrieved May ,Demographic Associations ,